Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
Shares of biopharmaceutical company Axsome Therapeutics ( AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes ...
After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...
Investor's Business Daily on MSN3d
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A WeekAxsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.
Axsome Therapeutics Inc. investors can proceed with a proposed class action alleging the drugmaker misled them about a ...
CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...
Axsome Therapeutics (NASDAQ:AXSM) traded lower in the premarket on Tuesday after the company said solriamfetol, its ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...
New York, New York-- (Newsfile Corp. - April 2, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ ...
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...
Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback